clinical trial · NCT04158934
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
Baxalta now part of Shire·—·active not recruiting·n = 207
Hemophilia AADYNOVI/ADYNOVATE
brief summary
The main aim of this study is to check for long-term side effects from ADYNOVI/ADYNOVATE prophylaxis in participants with haemophilia A when used under standard clinical practice in the real-world clinical setting.
started
Jul 9, 2020
primary completion
Feb 28, 2030
completion
Feb 28, 2030
last updated
Feb 18, 2026
official title
Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol